Clostridium Difficile Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

Clostridium Difficile Tests Market Report Overview

The Clostridium Difficile Tests market size was valued at $156 million in 2022. C. difficile is a highly contagious bacteria predominantly found in soil and can enter a person through the Fecal-oral route. The spore-forming ability of this bacteria makes it highly resistant to antibiotics. Risk factors associated with CDI are old age, recent hospital stay, and prolonged exposure to antibiotics. Symptoms of CDI are prolonged Diarrhea, abdominal pain, and tenderness, fever, and blood in stools.

Clostridium Difficile Tests Market Outlook 2022-2033 ($ Million)

For more insights on the Clostridium Difficile Tests market forecast, download a free sample report

The Clostridium Difficile Tests market research report is built to visualize quantitative market trends within in vitro diagnostics therapeutic areas. Furthermore, the model discusses in detail the impact of COVID-19 on the Clostridium Difficile Tests market for the year 2020 and beyond.

Clostridium Difficile Tests Market Dynamics

The Clostridium difficile tests market is expected to increase during the forecast period, largely due to increases in overall population size and thus the number of suspected infection cases. This Market is dominated by markets in North America and Europe, with fewer sales occurring in other regions. Diminished sales in the APAC, South American, and Middle East & Africa regions, continue to be negatively impacted by under-reporting of the disease and the lack of uniform testing algorithms.

While expansion of Clostridium difficile screening to asymptomatic patients would drive strong growth in the sales of these testing devices, primary participants indicate that this change in policy is unlikely to occur in the near future. Physician guidelines continue to recommend that only symptomatic patients should be tested for CDI and primary participants indicate that this advice is generally adhered to.

For additional Clostridium Difficile Tests market dynamics, download a free sample report

Clostridium Difficile Tests Market Segments

The key segments in the Clostridium Difficile Tests market are Clostridium Difficile Nucleic Acid Amplification Tests (NAATs), Clostridium Difficile Toxin Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Dual Toxin and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests, Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests. In 2022, the Clostridium Difficile Nucleic Acid Amplification Tests (NAATs) segment dominated the market share.

The market for NAATs is considerably stronger in the US and South Korea, due to the fact that a single NAAT is sometimes used to diagnose CDI in these two countries.  Additionally, the use of GDH EIA tests is strong in Europe and a number of other key markets, due to the widespread implementation of the two-step algorithm, as well as the cost-effectiveness and high positive predictive value of these devices.

Clostridium Difficile Tests Market Analysis by Segments, 2022 (%)

To know more about the Clostridium Difficile Tests market segments, download a free sample report

Clostridium Difficile Tests Market Segmentation by Regions

The key regions in the Clostridium Difficile Tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2022, North America emerged as the leading regional segment with the US being the largest contributor to the regional market.

Growth is expected to occur in the US, Canada, and Mexico, largely due to increases in overall population size and thus the number of suspected infection cases. The US Clostridium Difficile tests IVD market is large compared to many other countries, due to strong sales of NAAT devices.  Primary participants and secondary sources indicate that in many US institutions, NAAT is used as the initial method for diagnosing CDI. Conversely, in Canada and Mexico the device is used for initial testing of suspected CDI cases tend to be toxin EIA tests and GDH EIA tests, respectively.

Clostridium Difficile Tests Market Analysis by Regions, 2022 (%)

For more regional insights in the Clostridium Difficile Tests market, download a free sample report

Clostridium Difficile Tests Market – Competitive Landscape

The key companies in the Clostridium Difficile Tests market are bioMerieux SA, Meridian Bioscience Inc, TECHLAB Inc, Thermo Fisher Scientific Inc, LG Life Science LTD, Leica Microsystems Inc + Cepheid Inc, DiaSorin Molecular LLC + Luminex Corp, Microbiologics Inc, and American Type Culture Collection among others. In 2022, Leica Microsystems Inc + Cepheid Inc accounted for the highest Clostridium Difficile Tests market share and value.

Clostridium Difficile Tests Market Analysis by Companies, 2022 (%)

For more company insights into the Clostridium Difficile Tests market, download a free sample report

Segments Covered in this Report

Clostridium Difficile Tests Segment Outlook ($ Million, 2015-2033)

• Clostridium difficile Culture Tests
• Clostridium difficile Nucleic Acid Amplification Tests (NAATs)
• Clostridium difficile Toxin Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests
• Dual Toxin and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests
• Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests

Clostridium Difficile Tests Regional Outlook ($ Million, 2015-2033)

• Asia-Pacific
• Europe
• Middle East and Africa
• North America
• South and Central America

Key Inclusions of the market model are –

Currently marketed Clostridium Difficile Tests market and evolving competitive landscape –

• Insightful review of the key industry trends.
• Annualized total Clostridium Difficile Tests market revenue by segment and market outlooks from 2015-2033.
• Market-level data on units, average selling prices, and market values.

Global, Regional and Country level market specific insights –

• Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• SWOT analysis for the Clostridium Difficile Tests market.
• Competitive dynamics insights and trends provided for the Clostridium Difficile Tests market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: bioMerieux SA, Meridian Bioscience Inc, TECHLAB Inc, Thermo Fisher Scientific Inc, LG Life Science LTD, Leica Microsystems Inc + Cepheid Inc, DiaSorin Molecular LLC + Luminex Corp, Microbiologics Inc, and American Type Culture Collection.

Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for

• CMO executives who must have a deep understanding of the Clostridium Difficile Tests marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to –

• Understand the impact of COVID-19 on Clostridium Difficile Tests.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Clostridium Difficile Tests.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Clostridium Difficile Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Clostridium Difficile Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.